


## ILS-920

|                           |   |
|---------------------------|---|
| <b>Cat. No.:</b>          | HY-106345   |
| <b>CAS No.:</b>           | 892494-07-4   |
| <b>Molecular Formula:</b> | C <sub>57</sub> H <sub>86</sub> N <sub>2</sub> O <sub>14</sub>                                      |
| <b>Molecular Weight:</b>  | 1023.3  |
| <b>Target:</b>            | FKBP; Calcium Channel   |
| <b>Pathway:</b>           | Apoptosis; Autophagy; Immunology/Inflammation; Membrane Transporter/Ion Channel; Neuronal Signaling |
| <b>Storage:</b>           | Please store the product under the recommended conditions in the Certificate of Analysis.           |



### BIOLOGICAL ACTIVITY

|                                     |  |
|-------------------------------------|--|
| <b>Description</b>                  | ILS-920 is a nonimmunosuppressive Rapamycin analog with reduced immunosuppressive activity and potent neuroprotective activity. ILS-920 binds selectively to the immunophilin FKBP52 and to the $\beta$ 1-subunit of L-type voltage-gated calcium channels (VGCC). ILS-920 shows 200-fold selectivity for FKBP52 versus FKBP12 <sup>[1]</sup> .  |
| <b>IC<sub>50</sub> &amp; Target</b> | L-type calcium channel   |
| <b>In Vitro</b>                     | ILS-920 promotes neuronal survival and stimulates neurite outgrowth with potent neurotrophic activities in cortical neuronal cultures <sup>[1]</sup> .<br>ILS-920 can inhibit L-type Ca <sup>2+</sup> channels in rat hippocampal neurons and F-11 dorsal root ganglia (DRG)/neuroblastoma cells. ILS-920 can protect neurons from Ca <sup>2+</sup> -induced cell death by modulating Ca <sup>2+</sup> channels and promote neurite outgrowth via FKBP52 binding <sup>[1]</sup> .<br>MCE has not independently confirmed the accuracy of these methods. They are for reference only. |
| <b>In Vivo</b>                      | In a transient middle cerebral artery occlusion (tMCAO) model of ischemic stroke, ILS-920, administered 4 h postocclusion at 10 and 30 mg/kg, significantly reduces infarct volume by 24% and 23% in 72 h, respectively, and robustly enhances functional recovery measured by improvement in neurological deficits <sup>[1]</sup> .<br>MCE has not independently confirmed the accuracy of these methods. They are for reference only.  |

### REFERENCES

[1]. Ruan B, et al. Binding of rapamycin analogs to calcium channels and FKBP52 contributes to their neuroprotective activities. Proc Natl Acad Sci U S A. 2008 Jan 8;105(1):33-8.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA